OncoMatch/Clinical Trials/NCT04981509
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
Is NCT04981509 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Atezolizumab and Bevacizumab for hereditary leiomyomatosis and renal cell carcinoma.
Treatment: Atezolizumab · Bevacizumab · Erlotinib · Sodium Fluoride F-18 — This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage III, IV (AJCC v8)
Metastatic disease required
advanced RCC with measurable disease
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: bevacizumab (bevacizumab)
Exception: no prior bevacizumab therapy in the metastatic/advanced setting
no prior bevacizumab therapy in the metastatic/advanced setting
Cannot have received: PD-1 or PD-L1 inhibitor
Exception: no prior treatment with PD-1 or PD-L1 inhibitors in the metastatic/advanced setting
No prior treatment with PD-1 or PD-L1 inhibitors in the metastatic/advanced setting
Cannot have received: systemic therapy for kidney cancer
Exception: no prior systemic therapy to treat the patient's kidney cancer within 4 weeks or, if known, 5 half-lives of the prior agent (whichever is shorter) prior to cycle 1 day 1
Any prior systemic therapy to treat the patient's kidney cancer within 4 weeks or, if known, 5 half-lives of the prior agent (whichever is shorter) prior to cycle 1 day 1
Cannot have received: radiotherapy
Exception: radiotherapy < 2 weeks prior to cycle 1, day 1
Radiotherapy < 2 weeks prior to cycle 1, day 1
Cannot have received: investigational agent
Exception: treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1
Treatment with any other investigational agent within 4 weeks prior to cycle 1, day 1
Cannot have received: systemic immunostimulatory agent (interferon-alpha, interleukin-2)
Exception: treatment with systemic immunostimulatory agents within 6 weeks prior to cycle 1, day 1
Treatment with systemic immunostimulatory agents (including, but not limited to, interferon [IFN]-alpha or interleukin [IL]-2) within 6 weeks prior to cycle 1, day 1
Cannot have received: systemic immunosuppressive medication (prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, anti-TNF agents)
Exception: treatment with systemic immunosuppressive medications within 2 weeks prior to cycle 1, day 1; exceptions for acute, low dose, inhaled corticosteroids, mineralocorticoids
Treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 2 weeks prior to cycle 1, day 1
Lab requirements
Blood counts
Absolute neutrophil count >= 1,000/mcL; Platelets >= 100,000/mcL
Kidney function
Glomerular filtration rate (GFR) >= 30 mL/min/1.73 m^2; for pediatric patients (< 18 years of age) specific creatinine thresholds apply
Liver function
Total bilirubin <= 1.5 x institutional ULN (< 3 x upper limit of reference range in patients with known/suspected Gilbert's disease); AST/ALT <= 2.5 x institutional ULN (or <= 5 x upper limit of reference range if considered to be related to liver or bone metastases by the PI); Alkaline phosphatase <= 2.5 x institutional ULN (or <= 5 x upper limit of reference range if considered to be related to liver or bone metastases by the PI)
Cardiac function
Patients with a known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
Absolute neutrophil count >= 1,000/mcL; Platelets >= 100,000/mcL; Total bilirubin <= 1.5 x institutional upper limit of normal (ULN) (< 3 x upper limit of reference range in patients with known/suspected Gilbert's disease); AST/ALT <= 2.5 x institutional ULN (or <= 5 x upper limit of reference range if considered to be related to liver or bone metastases by the PI); Alkaline phosphatase <= 2.5 x institutional ULN (or <= 5 x upper limit of reference range if considered to be related to liver or bone metastases by the PI); GFR >= 30 mL/min/1.73 m^2; for pediatric patients (< 18 years of age) specific creatinine thresholds apply; NYHA class 2B or better
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UC San Diego Moores Cancer Center · La Jolla, California
- Emory University Hospital Midtown · Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute · Atlanta, Georgia
- Emory Saint Joseph's Hospital · Atlanta, Georgia
- Northwestern University · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify